CL2019001004A1 - Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos. - Google Patents

Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.

Info

Publication number
CL2019001004A1
CL2019001004A1 CL2019001004A CL2019001004A CL2019001004A1 CL 2019001004 A1 CL2019001004 A1 CL 2019001004A1 CL 2019001004 A CL2019001004 A CL 2019001004A CL 2019001004 A CL2019001004 A CL 2019001004A CL 2019001004 A1 CL2019001004 A1 CL 2019001004A1
Authority
CL
Chile
Prior art keywords
compounds
pyrazol
pyrimidin
amine
substituted derivatives
Prior art date
Application number
CL2019001004A
Other languages
English (en)
Inventor
Anja Giese
Thomas Müller
Niels Lindner
Jürgen Klar
Alexander Ehrmann
Jens Willwacher
David Engel
Andre Philippe Dieskau
Antje Kahnert
Alexey Gromov
Carsten Schmeck
Anna Lena Andreevski
Jan Dreher
Karl Collins
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of CL2019001004A1 publication Critical patent/CL2019001004A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS SUSTITUIDOS DE 6-(1H-PIRAZOL-1-IL)PIRIMIDIN4-AMINA DE LA FÓRMULA GENERAL (I) TAL COMO SE DESCRIBEN Y DEFINEN EN EL PRESENTE, PROCEDIMIENTOS PARA PREPARAR DICHOS COMPUESTOS, COMPUESTOS DE PRODUCTOS INTERMEDIOS ÚTILES PARA PREPARAR DICHOS COMPUESTOS, COMPOSICIONES FARMACÉUTICAS Y COMBINACIONES QUE COMPRENDEN DICHOS COMPUESTOS, Y EL USO DE DICHOS COMPUESTOS PARA LA FABRICACIÓN DE COMPOSICIONES FARMACÉUTICAS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES, EN PARTICULAR PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES CARDIOVASCULARES Y RENALES ,COMO AGENTE ÚNICO O EN COMBINACIÓN CON OTROS COMPUESTOS ACTIVOS.
CL2019001004A 2016-10-14 2019-04-12 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos. CL2019001004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16193953 2016-10-14

Publications (1)

Publication Number Publication Date
CL2019001004A1 true CL2019001004A1 (es) 2019-08-30

Family

ID=57136772

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001004A CL2019001004A1 (es) 2016-10-14 2019-04-12 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.

Country Status (28)

Country Link
US (2) US11208400B2 (es)
EP (1) EP3526212B1 (es)
JP (1) JP2019532961A (es)
KR (1) KR20190065402A (es)
CN (1) CN110191884A (es)
AR (1) AR109947A1 (es)
AU (1) AU2017341324A1 (es)
BR (1) BR112019007496A2 (es)
CA (1) CA3040166A1 (es)
CL (1) CL2019001004A1 (es)
CO (1) CO2019003761A2 (es)
CR (1) CR20190192A (es)
CU (1) CU24518B1 (es)
DO (1) DOP2019000099A (es)
EA (1) EA201990947A1 (es)
EC (1) ECSP19026563A (es)
GE (1) GEP20217269B (es)
IL (1) IL265923A (es)
JO (1) JOP20190080A1 (es)
MA (1) MA46514A (es)
MX (1) MX2019004347A (es)
PE (1) PE20191549A1 (es)
PH (1) PH12019500808A1 (es)
SG (1) SG11201903305XA (es)
TN (1) TN2019000114A1 (es)
TW (1) TW201825477A (es)
UY (1) UY37444A (es)
WO (1) WO2018069222A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110734428A (zh) * 2019-10-24 2020-01-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN115403524A (zh) * 2021-05-26 2022-11-29 浙江省化工研究院有限公司 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法
WO2024061768A1 (en) 2022-09-19 2024-03-28 Basf Se Azole pesticidal compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
AU3213200A (en) 1999-01-21 2000-08-07 Board Of Regents, The University Of Texas System Inhibitors of intestinal apical membrane na/phosphate co-transportation
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
WO2006074057A2 (en) 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP2146967A2 (en) * 2007-04-16 2010-01-27 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
JP2008296610A (ja) 2007-05-29 2008-12-11 Toyota Motor Corp 車両用動力伝達装置の制御装置
NZ609066A (en) * 2008-04-29 2014-07-25 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
RS56312B1 (sr) 2010-02-27 2017-12-29 Bayer Ip Gmbh Ariltriazoloni spojeni sa bis-arilom i njihova upotreba
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DK2588465T3 (en) * 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
ES2547890T3 (es) 2010-07-07 2015-10-09 Ardelyx, Inc. Compuestos y métodos para inhibir el transporte de fosfato
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2591354B1 (en) * 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2682394A1 (de) 2010-07-09 2014-01-08 Bayer Intellectual Property GmbH 1H-Pyrazolo[3,4-b]pyridin-Triazine Verbindungen und ihre Verwendung zur Behandlung bzw. Prophylaxe von Herz-Kreislauf-Erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
TW201323419A (zh) 2011-10-27 2013-06-16 Astellas Pharma Inc 經胺基烷基取代之ｎ－噻吩基苯甲醯胺衍生物
WO2013082756A1 (en) 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors ii
US10150742B2 (en) 2013-03-15 2018-12-11 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
TWI582083B (zh) * 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
SG11201703199UA (en) 2014-11-03 2017-05-30 Bayer Pharma AG Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
CN105631664A (zh) 2014-11-26 2016-06-01 华为终端（东莞）有限公司 一种非接触支付方法、装置及系统
US10266517B2 (en) * 2014-12-23 2019-04-23 Dana-Farber Cancer Institute, Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders
WO2018069892A1 (en) 2016-10-14 2018-04-19 Novartis Ag Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3525780B1 (en) 2016-10-14 2021-06-02 Institut Pasteur De Montevideo Pluripotent anti-inflammatory and metabolic modulators for the treatment of inflammation related conditions

Also Published As

Publication number Publication date
BR112019007496A2 (pt) 2019-09-10
PH12019500808A1 (en) 2020-01-20
IL265923A (en) 2019-06-30
JOP20190080A1 (ar) 2019-04-11
CN110191884A (zh) 2019-08-30
CA3040166A1 (en) 2018-04-19
US11208400B2 (en) 2021-12-28
SG11201903305XA (en) 2019-05-30
EA201990947A1 (ru) 2019-08-30
UY37444A (es) 2018-05-31
US20230065629A1 (en) 2023-03-02
CU24518B1 (es) 2021-06-08
PE20191549A1 (es) 2019-10-24
AR109947A1 (es) 2019-02-06
MA46514A (fr) 2019-08-21
DOP2019000099A (es) 2019-07-15
EP3526212B1 (en) 2021-12-22
MX2019004347A (es) 2019-07-01
EP3526212A1 (en) 2019-08-21
TN2019000114A1 (en) 2020-10-05
GEP20217269B (en) 2021-06-25
US20200055842A1 (en) 2020-02-20
ECSP19026563A (es) 2019-04-30
AU2017341324A1 (en) 2019-05-02
JP2019532961A (ja) 2019-11-14
CO2019003761A2 (es) 2019-04-30
KR20190065402A (ko) 2019-06-11
CU20190035A7 (es) 2019-11-04
WO2018069222A1 (en) 2018-04-19
TW201825477A (zh) 2018-07-16
CR20190192A (es) 2019-09-02

Similar Documents

Publication Publication Date Title
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CU20130033A7 (es) Imidazopiridazinas sustituidas
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
CL2019001004A1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
ECSP18056196A (es) Derivados de indano
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
UY37032A (es) Compuestos de heteroarilbenzimidazol
UY36983A (es) Pirazolopiridinaminas sustituidas